Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Todd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine
|
December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia
Melissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Cancer Discovery
|
May 4, 2019
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk, Stephen E Kurtz, Olga Nikolova, et al.
The Journal of Clinical Investigation
|
August 15, 2017
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A Ramos, Brandon Ballard, Huimin Zhang, et al.
Cancers
|
February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
Anupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood Advances
|
November 8, 2019
Replication timing alterations in leukemia affect clinically relevant chromosome domains
Juan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, et al.
Blood Cancer Discovery
|
September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Christopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Journal of the National Cancer Institute
|
July 4, 2024
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium
Eric S Schafer, Teresa Rushing, Kristine R Crews, et al.
The New England Journal of Medicine
|
May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
Julia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2016
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Todd M Cooper, Jeannette Cassar, Elena Eckroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2023
Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Olivia M Lucero, Ji-Ann Lee, Jenna Bowman, et al.
Cell Reports. Medicine
|
December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia
Melissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Cancer Discovery
|
May 4, 2019
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk, Stephen E Kurtz, Olga Nikolova, et al.
The Journal of Clinical Investigation
|
August 15, 2017
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A Ramos, Brandon Ballard, Huimin Zhang, et al.
Cancers
|
February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium
Anupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood Advances
|
November 8, 2019
Replication timing alterations in leukemia affect clinically relevant chromosome domains
Juan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, et al.
Blood Cancer Discovery
|
September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Christopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Journal of the National Cancer Institute
|
July 4, 2024
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium
Eric S Schafer, Teresa Rushing, Kristine R Crews, et al.
The New England Journal of Medicine
|
May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
Julia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Page
of 6